AZNCF News and Press, AstraZeneca Plc From 09/16/23

2023-09-16 08:26:36 ET Summary The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. IXJ: a global alternative to ...

2023-09-15 13:02:18 ET Summary Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second...

2023-09-03 03:45:00 ET Summary Shanghai GenFleet Technologies partners with Verastem in a deal worth up to $625.5 million for three preclinical small-molecule candidates for RAS pathway-driven cancers. Shanghai Kangpu Biopharmaceuticals raises $13.8 million in a B funding round to...

2023-08-24 02:20:26 ET Summary Bristol-Myers has a strong history of investment outperformance during equity bear markets and recessions. The company is uniquely undervalued, with a low 8x P/E and nearly 4% cash dividend yield. After a weak first half of 2023, shares may rebou...

2023-08-22 07:30:00 ET Summary The annual economic symposium at Jackson Hole is eagerly awaited for insights into the Fed's next policy actions. Powell will likely continue to be hawkish given the still-elevated inflation and strong activity data. But even beyond the Fed, insights...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-08-10 11:01:31 ET Summary Organon & Co. posted its Q2 2023 earnings on 8th August. The Merck spinouts' 3 main divisions are Women's Health, Biosimilars, and Established Brands. Total revenues were $1.6bn - up 4% ex-FX fluctuations - and diluted EPS was $0.95 - both ou...

2023-08-08 12:46:53 ET Summary China's economic recovery has turned out to be slower than expected, with growth forecasts reduced for 2023. But strong domestic consumption indicates that there are still pockets of recovery. Segments like jewelry, apparel, and medicines are doing w...